Clinical Trial: A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07560020) titled 'A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy' on April 07.

Brief Summary: This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Autosomal Dominant RYR1-Related Myopathy

Intervention: DRUG: Surlorian

300 mg administered once a day

O...